Other

Gruenenthal Gmbh

Magforce Ag

Rina Netzwerk Rna Technologien Gmbh

Volker A Erdmann

Thorsten Lamla

Wolfgang Stiege

Jens Kurreck

Jiang Gao

Jens Peter Furste

Monika Fischler

Rolf Bald

The present invention relates to an active substance release system containing two compounds. The first compound comprises a nanoparticle, combined with an oligonucleotide inhibition strand that is hybridized with a catalytically active nucleic acid. The second compound comprises a carrier, combined with a substrate molecule that is coupled to a therapeutic active substance. By means of external stimulation, the catalytically active nucleic acid of the first compound is released and specifically binds to the substrate molecule of the second compound. This leads to cleavage of the substrate molecule, whereby the active substance bound thereto is released.

Temperature dependent activation of catalytic nucleic acids for controlled active substance release

The invention relates to novel streptavidin binding peptides.

Streptavidin-binding peptide

Antisense oligodeoxynucleotides against VR1, corresponding nucleotide constructs, cells containing said nucleotide constructs, pharmaceutical and diagnostic substances, uses thereof in pain therapy, and methods for diagnosing symptoms related to VR1 and for identifying pain-modulating substances.

Antisense oligonucleotides against VR1

The invention relates to a method for gene expression in a cell-free transcription/translation system, the reaction solution containing all the components necessary for the transcription/translation mechanism, amino acids, nucleotides, metabolic components which provide energy and which are necessary for synthesis, and the proteins arising during translation being immobilized on a matrix.

Method for gene expression

A method is disclosed for identifying and producing L-nucleic acids which interact with a target molecule having a natural configuration, as well as the L-nucleic acids produced by this method. Also disclosed is the use of D-nucleic acids which bind to the optical antipode of the target molecule as a matrix for producing L-nucleic acids with an identical sequence, and pharmaceutical compositions and kits which contain the disclosed L-nucleic acids.

Growing community of inventors

Berlin, Germany

Volker A Erdmann